Jump Financial LLC Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Jump Financial LLC purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 11,417 shares of the company’s stock, valued at approximately $135,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Barclays PLC increased its stake in Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company’s stock valued at $5,302,000 after buying an additional 75,609 shares during the period. Virtu Financial LLC acquired a new position in Roivant Sciences in the 3rd quarter valued at approximately $207,000. Te Ahumairangi Investment Management Ltd increased its stake in Roivant Sciences by 19.9% in the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company’s stock valued at $2,313,000 after buying an additional 33,467 shares during the period. Tyro Capital Management LLC increased its stake in Roivant Sciences by 0.6% in the 3rd quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company’s stock valued at $20,252,000 after buying an additional 10,649 shares during the period. Finally, Retirement Systems of Alabama increased its stake in Roivant Sciences by 26.9% in the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after buying an additional 112,286 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Stock Up 1.6 %

ROIV stock opened at $11.19 on Tuesday. The company has a market capitalization of $7.98 billion, a price-to-earnings ratio of -74.60 and a beta of 1.25. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $13.06. The firm has a 50 day moving average of $10.35 and a two-hundred day moving average of $11.14.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, research analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Insider Activity at Roivant Sciences

In related news, CAO Rakhi Kumar sold 227,500 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares in the company, valued at approximately $1,702,843.52. This trade represents a 58.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Eric Venker sold 315,522 shares of the firm’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $11.06, for a total transaction of $3,489,673.32. Following the completion of the transaction, the chief operating officer now owns 959,457 shares in the company, valued at $10,611,594.42. The trade was a 24.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,395,541 shares of company stock worth $14,922,538. 7.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ROIV has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Monday, April 21st. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.